Literature DB >> 12959188

Ovarian cancer screening.

Nicole Urban1, Martin W McIntosh, Marin Andersen, Beth Y Karlan.   

Abstract

In an ongoing effort to design an efficacious, cost-effective ovarian cancer screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as mesothelin and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959188     DOI: 10.1016/s0889-8588(03)00063-7

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  22 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

3.  Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Authors:  Amelie M Lutz; Sunitha V Bachawal; Charles W Drescher; Marybeth A Pysz; Jürgen K Willmann; Sanjiv Sam Gambhir
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

4.  HE4: a new potential early biomarker for the recurrence of ovarian cancer.

Authors:  Emanuela Anastasi; Giulia Giovanna Marchei; Valentina Viggiani; Giuseppina Gennarini; Luigi Frati; Maria Gabriella Reale
Journal:  Tumour Biol       Date:  2010-01-23

5.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Authors:  Nathalie Scholler; Kimberly A Lowe; Lindsay A Bergan; Archana V Kampani; Vivian Ng; Robin M Forrest; Jason D Thorpe; Jenny A Gross; Barbara M Garvik; Ronny Drapkin; Garnet L Anderson; Nicole Urban
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

6.  Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Authors:  Kimberly A Lowe; Chirag Shah; Erin Wallace; Garnet Anderson; Pamela Paley; Martin McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay Bergan; Jason Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

7.  The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.

Authors:  Qiong Zhang; Cong-Rong Wang; Juan-Ping Yu; Qiang Ma; Wei-Wen Xu
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

8.  The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.

Authors:  Kimberly A Lowe; M Robyn Andersen; Nicole Urban; Pamela Paley; Charles W Dresher; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2009-05-07       Impact factor: 5.482

9.  Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

Authors:  M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Dresher; Pamela Paley; Nicole Urban
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

Review 10.  Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.